There he was again, same time every Wednesday morning, standing in front of a copse of a 50-foot high, skinny-trunked Carolina Pine flanking the road to my house: the man
The Food and Drug Administration is on the verge of announcing one of its most contentious decisions in years: the fate of an Alzheimer’s drug that could be the first treatment approved after nearly two decades of failed efforts to find ways to curb the debilitating disease.
If the agency approves it, aducanumab would be the first new Alzheimer’s treatment since 2003. Patients are desperate for new options, but some scientists say there isn’t enough evidence it works.
The FDA is scheduled to announce a decision on aducanumab by Monday in one of its most closely watched rulings in years. The backstory of the drug, intended to delay cognitive decline in the early phase of Alzheimer’s disease, has been marked by soaring hopes and disheartening setbacks.